Steven Lichtman
Stock Analyst at Oppenheimer
(2.98)
# 1,534
Out of 5,050 analysts
71
Total ratings
41.18%
Success rate
12.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $16.26 | +35.30% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $319.82 | +14.13% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $100.02 | +24.98% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $55.00 | +85.45% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $88.50 | +52.54% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.63 | +113.14% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $73.97 | +48.71% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $92.20 | +1.95% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $9.37 | +593.70% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $15.59 | -29.44% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $12.02 | -0.17% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $87.55 | -0.63% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.52 | +573.08% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $356.03 | -19.11% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $83.86 | +25.21% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $26.55 | +464.97% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $70.10 | +21.26% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $16.26
Upside: +35.30%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $319.82
Upside: +14.13%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $100.02
Upside: +24.98%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $55.00
Upside: +85.45%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $88.50
Upside: +52.54%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.63
Upside: +113.14%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $73.97
Upside: +48.71%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $92.20
Upside: +1.95%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $9.37
Upside: +593.70%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $15.59
Upside: -29.44%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $12.02
Upside: -0.17%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $87.55
Upside: -0.63%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.52
Upside: +573.08%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $356.03
Upside: -19.11%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $83.86
Upside: +25.21%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $26.55
Upside: +464.97%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $70.10
Upside: +21.26%